Latch ARR hit $15M, marking a 5x increase quarter-over-quarter, and is targeting $130M by 2026. The company is currently closing a Series B round at a valuation of $500M.

Kenny Workman (CTO of LatchBio) outlines a vision for AI agents in biology, arguing that 2026 is the year these systems move from general code to specialized molecular data analysis.

  • The "Coding" Analogy: Workman argues that just as coding agents had to master basic languages before building complex software, biology agents must first master concrete measurements (like spatial assays) before they can reason about complex disease mechanisms.

  • A Tiered Roadmap:

    1. Procedural Skill: Mastering the analysis of raw data.

    2. Emergent Reasoning: Interpreting what those measurements mean biologically.

    3. Synthesis: Combining data types to support high-stakes drug development decisions.

Instead of a direct sales approach, they are white-labeling their platform through measurement tech companies like TakaraBio and Vizgen. This allows scientists to move from "sample to answer" using agents bundled with their laboratory hardware.